Zobrazeno 71 - 80
of 152
pro vyhledávání: '"Zhongyu Yuan"'
Autor:
Yanhong Su, Zhongyu Yuan, Xinyue Wang, Shusen Wang, Jia Jia Huang, Xiwen Bi, Wei Shi, Zhangzan Huang, Wen Xia, Yanxia Shi, JiBin Li
Publikováno v:
Oncologist
Lessons Learned Moxifloxacin plus continuation of the previous treatment of physician's choice shows promising efficacy in patients with metastatic breast cancer. The addition of moxifloxacin shows well-tolerated toxicities. Background Recent studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb0713d6036a06cac11c17b6a6065c9b
https://europepmc.org/articles/PMC7543292/
https://europepmc.org/articles/PMC7543292/
Publikováno v:
Environmental pollution (Barking, Essex : 1987). 266(Pt 2)
Lifetime cancer risk and exposure of daily commuters to polycyclic aromatic hydrocarbons (PAHs) in cities of Northwest China were determined from a study of street dust samples obtained from bus stops in Qingyang city. The sum of 16 priority PAHs (Σ
Publikováno v:
Endocrine-related cancer. 27(4)
The significance of androgen receptor (AR) in metastatic breast cancer (MBC) remains unclear, and it is still largely unknown how AR expression level influences HER2-positive tumors. This study aimed to investigate the prognostic and predictive value
Autor:
Qiufan Zheng, Qianyi Lu, Ruoxi Hong, Kaping Lee, Fei Xu, Shusen Wang, Zhongyu Yuan, Yanxia Shi, Yuan Li, Qinglian Zhai, Wen Xia, Kuikui Jiang
Publikováno v:
Cancer Communications
Background Real‐world data of the CM regimen [cyclophosphamide (CTX) plus methotrexate (MTX)] in metronomic pattern for advanced breast cancer is limited to small‐sample or retrospective studies. This study was aimed to determine the effectivenes
Autor:
Qianyi Lu, Tao Qin, Fei Xu, Yinduo Zeng, Wen Xia, Qiufan Zheng, Kaping Lee, Kai Zhang, Ge Qin, Man Tek Kong, Ruoxi Hong, Yanxia Shi, Zhongyu Yuan, Shusen Wang
Publikováno v:
Translational Cancer Research. 7:659-667
Autor:
Anthony Gonçalves, Gilles Houvenaeghel, Fei Xu, Zhongyu Yuan, Rongzhen Luo, Shusen Wang, Haifeng Li, Riqing Huang, Alexandre de Nonneville, Xin An, Xuefen Lei, JiBin Li, Yanxia Shi, Cong Xue
Publikováno v:
CancerReferences. 126
Background Current guidelines recommend adjuvant chemotherapy for patients with small, lymph node-negative, triple-negative breast cancer (TNBC) measuring >5 mm (T1b disease), but clinical evidence to support this recommendation is lacking. Thus, the
Autor:
Ying Ouyang, Jun Li, Xianqiu Wu, Liping Ye, Chuyong Lin, Junling Liu, Qingyuan Li, Bin Wang, Zhongyu Yuan
Publikováno v:
The Journal of Pathology. 244:71-83
Triple-negative breast cancer (TNBC) represents the most aggressive subtype of breast cancer, with a high incidence of distant metastasis; however, the underlying mechanism for this frequent recurrence remains unclear. Herein, we show that synaptopod
Autor:
Haoran Xu, Qiang Zhang, Wenzhuo Ma, Xiaojie Zhou, Xiaobo Yang, Ziyang Liu, Zhongyu Yuan, Hongbin Shi, Jiahao Shan
Publikováno v:
Journal of Men's Health. 18:29
Background and objective: This study combined two clinical indicators (age and prostate volume (PV)) to generate age to PV (AVR) ratio, whose diagnostic value for prostate cancer (PCa) was examined based on prostate specific antigen (PSA) in the ran
Autor:
Qing Qu, Zhongsheng Tong, Zhongyu Yuan, Jiayang Zhang, Ruyan Zhang, Youzhi Tong, Wei Li, Hanfang Jiang, Huiping Li, Yongmei Yin, Cuizhi Geng, Quchang Ouyang, Kunwei Shen, Qiaoxia Zhou, Ran Ran, Xiaoyan Zhu, Luping Meng, Zhen Yi, Yaxin Liu, Xunwei Dong
Publikováno v:
Journal of Clinical Oncology. 39:1019-1019
1019 Background: Androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast cancer. AR is expressed in 60% to 80% of breast cancers. Recent studies have shown the association between AR signaling and tumor carcinogenesis
Autor:
Cong Xue, Xin Hua, Fei Xu, Ying Lin, Ruoxi Hong, Lehong Zhang, Yanxia Shi, Yuan-Qi Zhang, Kuikui Jiang, Yong-Yi Zhong, Zhongyu Yuan, Shusen Wang, Jia Jia Huang, Zhiyong Wu, Wen Xia, Jian-Li Zhao, Xiwen Bi, Xin An
Publikováno v:
Journal of Clinical Oncology. 39:1003-1003
1003 Background: For metastatic breast cancer with hormone receptor-positive and HER2-positive, no evidence showed that which first-line regimens were preferred, either anti-HER2 therapy plus endocrine therapy or anti-HER2 therapy plus chemotherapy.